At the time of writing, Cellectar Biosciences Inc [CLRB] stock is trading at $3.78, up 12.84%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLRB shares have gain 4.13% over the last week, with a monthly amount glided 9.72%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 14, March 2024, Cellectar Biosciences to Present at the 36th Annual Roth Conference. In a post published today on Yahoo Finance, Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details of the fireside chat are as follows:.
From an analyst’s perspective:
On September 13, 2019, ROTH Capital initiated with a Buy rating. Ladenburg Thalmann started tracking the stock assigning a Buy rating and suggested a price target of $2.70 on December 21, 2016.
For the past year, the stock price of Cellectar Biosciences Inc fluctuated between $1.30 and $4.45. Cellectar Biosciences Inc [NASDAQ: CLRB] shares were valued at $3.78 at the most recent close of the market.
Analyzing the CLRB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.75, Equity is -16.68 and Total Capital is -6.66. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.54 points at the first support level, and at 3.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.00, and for the 2nd resistance point, it is at 4.21.
Cellectar Biosciences Inc [CLRB] reported earnings per share of -$1.28 for its fiscal quarter that ended on 9/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.21/share, meaning a difference of -$0.07 and a surprise factor of -5.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2022 were -$1.22 per share as compared to estimates of -$1.03 per share, a difference of -$0.19 representing a surprise of -18.40%.
Ratios To Look Out For
It is important to note that Cellectar Biosciences Inc [NASDAQ:CLRB] has a current ratio of 1.22. Further, the Quick Ratio stands at 1.22, while the Cash Ratio is 1.15.
